Drugs / Mitoquinone/mitoquinol mesylate
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05886816 | Mar 2024 → Jul 2026 overdue | COVID-19 | University of Texas Southwestern Medical Center | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mitoquinone/mitoquinol mesylate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05886816 ↗ |
| Route | Oral | “MitoQ pills 20 mg orally daily taken during the study and initiated within 3 days post exposure.” NCT05886816 ↗ |